Skip to main content
SpringerLink
Log in

Vitamin D-binding protein-derived macrophage-activating factor, GcMAF, and prostate cancer

  • Letter to the editors
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Rigamonti N, Bellone M (2012) Prostate cancer, tumor immunity and a renewed sense of optimism in immunotherapy. Cancer Immunol Immunother 61(4):453–468. doi:10.1007/s00262-012-1216-6

    Article  PubMed  CAS  Google Scholar 

  2. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. doi:10.1056/NEJMoa1200694

    Google Scholar 

  3. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. doi:10.1056/NEJMoa1200690

    Google Scholar 

  4. Dulos J, Carven GJ, van Boxtel SJ, Evers S, Driessen-Engels LJ, Hobo W, Gorecka MA, de Haan AF, Mulders P, Punt CJ, Jacobs JF, Schalken JA, Oosterwijk E, van Eenennaam H, Boots AM (2012) PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer. J Immunother 35(2):169–178. doi:10.1097/CJI.0b013e318247a4e700002371-201202000-00008

    Article  PubMed  CAS  Google Scholar 

  5. Yamamoto N, Homma S (1991) Vitamin D3 binding protein (group-specific component) is a precursor for the macrophage-activating signal factor from lysophosphatidylcholine-treated lymphocytes. Proc Natl Acad Sci USA 88(19):8539–8543

    Article  PubMed  CAS  Google Scholar 

  6. Yamamoto N, Suyama H (2008) Immunotherapy for prostate cancer with Gc protein-derived macrophage-activating factor, GcMAF. Transl Oncol 1(2):65–72

    PubMed  Google Scholar 

  7. Rehder DS, Nelson RW, Borges CR (2009) Glycosylation status of vitamin D binding protein in cancer patients. Protein Sci 18(10):2036–2042. doi:10.1002/pro.214

    Article  PubMed  CAS  Google Scholar 

  8. Kanda S, Mochizuki Y, Miyata Y, Kanetake H, Yamamoto N (2002) Effects of vitamin D(3)-binding protein-derived macrophage activating factor (GcMAF) on angiogenesis. J Natl Cancer Inst 94(17):1311–1319

    Article  PubMed  CAS  Google Scholar 

  9. Gregory KJ, Zhao B, Bielenberg DR, Dridi S, Wu J, Jiang W, Huang B, Pirie-Shepherd S, Fannon M (2010) Vitamin D binding protein-macrophage activating factor directly inhibits proliferation, migration, and uPAR expression of prostate cancer cells. PLoS One 5(10):e13428. doi:10.1371/journal.pone.0013428

    Article  PubMed  Google Scholar 

Download references

Confict of interest

None.

Author information

Author notes

  1. Nicolò Rigamonti

    Present address: The Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, Swiss Federal Institute of Technology, Lausanne (EPFL), 1015, Lausanne, Switzerland

Authors and Affiliations

  1. Cellular Immunology Unit, PIBIC, Division of Immunology Transplantation and Infectious Disease, San Raffaele Scientific Insitute, Via Olgettina 58, 20132, Milan, Italy

    Matteo Bellone & Nicolò Rigamonti

Authors
  1. Matteo Bellone
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nicolò Rigamonti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Matteo Bellone.

Additional information

This is the authors' response to a Letter to the Editors by Mostafa Ghanei, Majid Shohrati, and Amin Saburi (Cancer Immunol Immunother. 2012) commenting on the article Rigamonti N, Bellone M. Prostate cancer, tumor immunity and a renewed sense of optimism in immunotherapy (Cancer Immunol Immunother. 61:453-468, 2012)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bellone, M., Rigamonti, N. Vitamin D-binding protein-derived macrophage-activating factor, GcMAF, and prostate cancer. Cancer Immunol Immunother 61, 2377–2378 (2012). https://doi.org/10.1007/s00262-012-1310-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00262-012-1310-9

Keywords

Search

Navigation